Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1175175 (
SARS
)
19,188
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interferons (IFNs) control viral infections by inducing expression of IFN-stimulated genes (ISGs) that restrict distinct steps of viral replication. We report herein that
gamma-interferon-inducible lysosomal thiol reductase
(
GILT
), a lysosome-associated ISG, restricts the infectious entry of selected enveloped RNA viruses. Specifically, we demonstrated that
GILT
was constitutively expressed in lung epithelial cells and fibroblasts and its expression could be further induced by type II interferon. While overexpression of
GILT
inhibited the entry mediated by envelope glycoproteins of
SARS
coronavirus (SARS-CoV), Ebola virus (EBOV) and Lassa fever virus (LASV), depletion of
GILT
enhanced the entry mediated by these viral envelope glycoproteins. Furthermore, mutations that impaired the thiol reductase activity or disrupted the N-linked glycosylation, a posttranslational modification essential for its lysosomal localization, largely compromised
GILT
restriction of viral entry. We also found that the induction of
GILT
expression reduced the level and activity of cathepsin L, which is required for the entry of these RNA viruses in lysosomes. Our data indicate that
GILT
is a novel antiviral ISG that specifically inhibits the entry of selected enveloped RNA viruses in lysosomes
via
disruption of cathepsin L metabolism and function and may play a role in immune control and pathogenesis of these viruses.
...
PMID:GILT restricts the cellular entry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassa fever virus. 3163 85